Steve Gilman

(Dr. Steven Gilman Ph.D.)

Currently holds positions in SCYNEXIS Inc, Cubist Pharmaceuticals LLC, Momenta Pharmaceuticals Inc, Vericel Corp and Akebia Therapeutics Inc

Positions

Position Company Period
Director SCYNEXIS Inc Feb. 25, 2015 -
Executive Vice President - Research and Development, Chief Scientific Officer Cubist Pharmaceuticals LLC Sept. 7, 2010 -
Independent Director Momenta Pharmaceuticals Inc June 22, 2016 -
Independent Director Vericel Corp Jan. 1, 2017 -
Independent Director Akebia Therapeutics Inc Dec. 12, 2018 -
Chairman of the Board, President, Chief Executive Officer ContraFect Corp Jan. 1, 2017 - April 2, 2019
Independent Director Keryx Biopharmaceuticals Inc March 31, 2016 - Dec. 12, 2018
Chairman of the Board, Chief Executive Officer ContraFect Corp July 21, 2016 - Jan. 1, 2017
Director Vericel Corp Jan. 6, 2015 - Jan. 1, 2017
Chairman of the Board, Interim Chief Executive Officer ContraFect Corp March 21, 2016 - July 21, 2016
Executive Chairman of the Board ContraFect Corp May 20, 2015 - March 21, 2016
Steve Gilman's trades of SCYNEXIS Inc's stock


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PS: Planned sale, O: Option / Other
Notification date Transaction date B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2024-10-18 2024-10-16
US Vericel Corp (VCEL)
PS Planned sale
5,833 -34.7%
41.36
USD 241,253 		5,833 -34.7% 41.36 USD 241,253
2024-10-04 2024-10-02
US Vericel Corp (VCEL)
PS Planned sale
5,833 -34.7%
40.35
USD 235,362 		5,833 -34.7% 40.35 USD 235,362
2024-09-20 2024-09-18
US Vericel Corp (VCEL)
PS Planned sale
5,834 -34.7%
45.54
USD 265,680 		5,834 -34.7% 45.54 USD 265,680
2024-09-05 2024-09-04
US Vericel Corp (VCEL)
PS Planned sale
5,000 -31.2%
48.58
USD 242,900 		5,000 -31.2% 48.58 USD 242,900
2022-06-07 2022-06-03
PS Planned sale
4,567 -9.5%
0.36
USD 1,653 		4,567 -9.5% 0.36 USD 1,653
2022-05-02 2022-04-29
US Vericel Corp (VCEL)
PS Planned sale
900 -14.8%
30.94
USD 27,846 		900 -14.8% 30.94 USD 27,846
2021-12-01 2021-11-29
US Vericel Corp (VCEL)
PS Planned sale
5,000 -58.8%
39.17
USD 195,855 		5,000 -58.8% 39.17 USD 195,855
2021-10-28 2021-10-27
US Vericel Corp (VCEL)
PS Planned sale
5,000 -58.8%
50.57
USD 252,870 		5,000 -58.8% 50.57 USD 252,870
2021-10-01 2021-09-30
US Vericel Corp (VCEL)
PS Planned sale
5,000 -58.8%
48.85
USD 244,255 		5,000 -58.8% 48.85 USD 244,255
2021-06-09 2021-06-07
PS Planned sale
4,567 -8.7%
3.32
USD 15,163 		4,567 -8.7% 3.32 USD 15,163
2020-12-23 2020-12-21
US SCYNEXIS Inc (SCYX)
B Purchase
4,000 +inf%
6.25
USD 25,000 		4,000 +inf% 6.25 USD 25,000
2020-08-07 2020-08-05
PS Planned sale
13,000 -62.5%
32.75
USD 425,750 		13,000 -62.5% 32.75 USD 425,750
2020-07-30 2020-07-29
PS Planned sale
10,000 -56.2%
29.70
USD 297,000 		10,000 -56.2% 29.70 USD 297,000
2020-07-23 2020-07-22
PS Planned sale
10,000 -56.2%
33.23
USD 332,300 		10,000 -56.2% 33.23 USD 332,300
2020-06-09 2020-06-08
PS Planned sale
4,567 -10.5%
12.08
USD 55,169 		4,567 -10.5% 12.08 USD 55,169
2019-05-03 2019-05-01
US Vericel Corp (VCEL)
PS Planned sale
7,500 -100.0%
16.81
USD 126,095 		7,500 -100.0% 16.81 USD 126,095
2019-03-04 2019-02-28
US Vericel Corp (VCEL)
PS Planned sale
7,500 -100.0%
18.02
USD 135,129 		7,500 -100.0% 18.02 USD 135,129
// ... existing code ... // ... rest of the file ...